Asia Pacific Personalized Cancer Vaccine Market Size & Outlook
Related Markets
Asia Pacific personalized cancer vaccine market highlights
- The Asia Pacific personalized cancer vaccine market generated a revenue of USD 49.6 million in 2024.
- The market is expected to grow at a CAGR of 46.3% from 2025 to 2030.
- In terms of segment, dendritic cell was the largest revenue generating type in 2024.
- Dendritic Cell is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 49.6 million |
| Market revenue in 2030 | USD 365.9 million |
| Growth rate | 46.3% (CAGR from 2025 to 2030) |
| Largest segment | Dendritic cell |
| Fastest growing segment | Dendritic Cell |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Dendritic Cell |
| Key market players worldwide | Dendreon, Gritstone bio, CureVac NV Ordinary Shares, Stemirna, Elicio Therapeutics, Evaxion Biotech, Imugene, Nouscom |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.8% of the global personalized cancer vaccine market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 365.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Personalized Cancer Vaccine Market Scope
Personalized Cancer Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nouscom | View profile | 11-50 | Basel, Basel-Stadt, Switzerland, Europe | https://nouscom.com/ |
| Imugene | View profile | 51-100 | Sydney, New South Wales, Australia, Oceania | https://www.imugene.com/ |
| Evaxion Biotech | View profile | 11-50 | Copenhagen, Hovedstaden, Denmark, Europe | http://evaxion-biotech.com/ |
| Elicio Therapeutics | View profile | 11-50 | Cambridge, Massachusetts, United States, North America | https://elicio.com |
| Stemirna | View profile | 11-50 | Beijing, Beijing, China, Asia | http://www.stemirna.com/ |
| Gritstone bio | View profile | 101-250 | Emeryville, California, United States, North America | https://gritstonebio.com |
| Dendreon | View profile | 1001-5000 | Seattle, Washington, United States, North America | http://www.dendreon.com/ |
| CureVac NV Ordinary Shares | View profile | 1100 | Friedrich-Miescher-Strasse 15, Tubingen, BW, Germany, 72076 | https://www.curevac.com |
Asia Pacific personalized cancer vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to personalized cancer vaccine market will help companies and investors design strategic landscapes.
Dendritic cell was the largest segment with a revenue share of 110.08% in 2024. Horizon Databook has segmented the Asia Pacific personalized cancer vaccine market based on dendritic cell covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Asia Pacific personalized cancer vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific personalized cancer vaccine market databook
-
Our clientele includes a mix of personalized cancer vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific personalized cancer vaccine market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific personalized cancer vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific personalized cancer vaccine market size, by country, 2018-2030 (US$M)
Asia Pacific Personalized Cancer Vaccine Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
